A Phase 2 interventional study of Aromatase Inhibitor and Bevacizumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 3 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-09.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies testing Aromatase inhibitors in Breast Neoplasms — 53 open to participants now, 81 under way, 22 of them phase 3. A drug class: Aromatase inhibitors · Breast Neoplasms.
Among the 349 studies testing Aromatase inhibitors in Breast Neoplasms, this one is the 140th largest by enrollment of the 341 interventional ones that give a count, is one of 20 that started in 2008, is one of 166 in phase 2, and was the 128th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →53 of the 349 studies testing Aromatase inhibitors in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
European Institute of Oncology · Sites in Italy
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 50+ · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+ · Women only
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 181 · Phase 3 107 · Phase 4 28
First in 1990; this study’s year is marked. 20 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 112 across the 341 interventional studies. Of the 225 that completed or were terminated, 96 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 349 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 86th largest by enrollment of the 170 interventional ones that give a count, is one of 11 that started in 2008, is one of 65 in phase 2, and was the 40th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
15 of the studies testing Aromatase inhibitors in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT04486911Shengjing HospitalPyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial | 2026-12-01 |
| NCT05286437National Cancer Centre, SingaporePhase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole | 2026-12-31 |
| NCT07492394Hebei Medical University Fourth HospitalDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 349 studies testing Aromatase inhibitors in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of bevacizumab in combination with chemotherapy or endocrine therapy, as preoperative treatment, in participants with HER2 negative breast cancer. Participants will be randomized to receive either chemotherapy (FEC100: Epirubicine 100 milligrams per square meter [mg/m\^2], 5-fluorouracil 600 mg/m\^2, and cyclophosphamide 600 mg/m\^2] for 12 weeks followed by taxane (paclitaxel/docetaxel) for 12 weeks or endocrine therapy (an aromatase inhibitor] daily for 24 weeks) with or without bevacizumab (15 milligrams per kilogram [mg/kg] as intravenous [IV] infusion every 3 weeks up 24 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks.
Drug: Epirubicine · Drug: 5-Fluorouracil (5FU) · Drug: Cyclophosphamide · Drug: Paclitaxel · Drug: Docetaxel
Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. Participants will also receive concurrent treatment with bevacizumab every 3 weeks for 24 weeks.
Drug: Bevacizumab · Drug: Epirubicine · Drug: 5-Fluorouracil (5FU) · Drug: Cyclophosphamide · Drug: Paclitaxel · Drug: Docetaxel
Participants will receive aromatase inhibitor therapy at discretion of the investigator for a period of 24 weeks.
Drug: Aromatase Inhibitor
Participants will receive aromatase inhibitor therapy at discretion of the investigator and concurrent treatment with bevacizumab for a period of 24 weeks.
Drug: Aromatase Inhibitor · Drug: Bevacizumab
Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
Also known as: Avastin
Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.
Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Percentage of Participants With Messenger Ribonucleic Acid (mRNA) Markers of Pathological Complete Response, as Assessed by Magnetic Resonance Imaging (MRI)
Time frame: Baseline up to end of study treatment (approximately 24 weeks)
Percentage of Participants With Objective Pathological Complete Response, as Assessed by Clinical Assessment
Time frame: Baseline up to end of study treatment (approximately 24 weeks)
Percentage of Participants With Type of Surgery
Percentage of participants with different surgery types (for example, Mastectomy, Tumorectomy/Breast conserving therapy (BCT), and Tumorectomy followed by mastectomy) will be reported.
Time frame: At Surgery (Between Weeks 24 and 25)
Percentage of Participants With Axillary Lymph Node Dissection Performed
Time frame: At Surgery (Between Weeks 24 and 25)
Pathological Tumor Size, as Assessed by Histopathological Examination
Time frame: At Surgery (Between Weeks 24 and 25)
Percentage of Participants With Presence of Tumor Cells Close to Resection Margin
Time frame: At Surgery (Between Weeks 24 and 25)
Percentage of Participants With Tumor Deposit in Other Body Parts
Time frame: At Surgery (Between Weeks 24 and 25)
Tumor Free Resection Margin
Time frame: At Surgery (Between Weeks 24 and 25)
Pathological Tumor Size as Measure Using Caliper
Time frame: Cycles 1 to 10 (cycle length=21 days), and Week 25
Pathological Tumor Size as Measure Using MRI
Time frame: Baseline, Weeks 12 and 25
Pathological Tumor Size as Measure Using Mamography
Time frame: Baseline, Weeks 12 and 25
Pathological Breast Tumor Size as Measure Using Ultrasound
Time frame: Baseline, Weeks 12 and 25
Pathological Axilla Tumor Size as Measure Using Ultrasound
Time frame: Baseline, Weeks 12 and 25
Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
Time frame: Screening, Cycles 1 to 10 (cycle length=21 days), and Week 25
Percentage of Participants With Lymph Node Involvement
Time frame: Cycles 1 to 10 (cycle length=21 days), and Week 25
Percentage of Participants With Objective Tumor Response, as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)
Time frame: Weeks 12 and 25
Percentage of Participants With New Lesions
Time frame: Weeks 12 and 25
Percentage of Participants With Molecular Changes in Protein Kinase Expression
Time frame: Baseline up to end of study treatment (approximately 24 weeks)
Percentage of Participants With Molecular Changes in Messenger Ribonucleic Acid (mRNA)/microRNA(miRNA)
Time frame: Baseline up to end of study treatment (approximately 24 weeks)
Percentage of Participants With Molecular Changes in Protein Expression
Time frame: Baseline up to end of study treatment (approximately 24 weeks)
Percentage of Participants With Single Nucleotide Polymorphism (SNP) Profiles Predicting Treatment Response
Time frame: Baseline up to end of study treatment (approximately 24 weeks)
Percentage of Participants With Treatment-Induced Changes in Tumor Cells as Determined by Number of Disseminated Tumor Cells in Bone Marrow
Time frame: Baseline up to end of study treatment (approximately 24 weeks)
Percentage of Participants With Treatment-Induced Changes in Tumor Cells as Determined by Number of Circulating Tumor Cells in Peripheral Blood
Time frame: Baseline up to end of study treatment (approximately 24 weeks)
Ran from Nov 2008 to primary completion in Nov 2022, 168 months.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 168 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aromatase inhibitors · Bevacizumab · Epirubicin · Fluorouracil · Cyclophosphamide · Paclitaxel · Docetaxel